For More Videos Like this Subscribe to OncologyTube eNewsletter: share.hsforms.com/1dpwSptdCQP...
Timecodes:
0:00 - Intro
0:19 - What are the most significant predictors of therapy-related myeloid neoplasms (tMNs) identified in your study, and how were these incorporated into the tMN risk score (TMNRS)?
1:48 - Can you discuss the methodology used for developing and validating the TMNRS, including the use of the SEER-Medicare database and the Χ2 test for identifying risk factors?
3:51 - How does the TMNRS differentiate between various risk groups among cancer survivors, and what are the implications for clinical practice in terms of screening and monitoring?
6:15 - What are the limitations of the TMNRS model as indicated by its c-statistic range (0.62-0.68), and what steps are planned to improve its predictive performance using molecular data?
7:06 - How might the integration of a web-based calculator for TMNRS improve the accessibility and utility of this tool in clinical settings, and what are the anticipated benefits for patient management?
Join us at ASCO 2024 as Dr. Abhay Singh from the Cleveland Clinic dives deep into the groundbreaking research on Therapy-Related Myeloid Neoplasm Risk Score (TMN-RS). In this insightful interview, Dr. Singh discusses the development of the TMN-RS, highlighting its significance in identifying novel predictors of TMN, such as a prior history of autoimmune diseases and exposure to granulocyte colony-stimulating factors.
Dr. Singh explains how the study, encompassing data from nearly a million patients, leverages a combined database of SEER and Medicare claims to provide a detailed and comprehensive analysis. The TMN-RS not only offers a novel way to predict the absolute risk of developing myeloid neoplasms but also serves as a valuable tool for oncologists in making informed treatment decisions.
Key Highlights:
Development and significance of TMN-RS
Identification of novel predictors of TMN
Importance of combining SEER and Medicare databases
Applications of TMN-RS in clinical decision-making
Future plans for enhancing the TMN-RS with molecular data
Watch till the end to understand how this innovative risk score can influence treatment strategies and improve patient outcomes. Don’t forget to like, comment, and subscribe for more updates from ASCO 2024!